NEW YORK (GenomeWeb) – Merck KGaA today said that it will collaborate with Sysmex Inostics on the development of a RAS biomarker mutation test for metastatic colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.